ClinicalTrials.gg
Active, not recruitingNCT04720157PSMAdditionUpdated Nov 4, 2026Results posted

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A Phase 3 interventional study of 177Lu-PSMA-617 and 68Ga-PSMA-11 in Prostatic Neoplasms, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 164 sites in 19 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know

Updated Nov 4, 2026Results postedStudy documents posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,144
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Enrollment
Largest of 41
1,144 · median 49
Started
2021
with 4 others
Phase 3
4 of 41
1 open now
Primary completion
2025-01
later than 2 of 30 live
Registered
12th of 41
by date
Lead sponsor
6 of 41
Novartis Pharmaceuticals

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one has the largest enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, reaches primary completion later than 2 of the 30 other live ones, and was the 12th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.

Read the detailed description

In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC were to be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.

The primary objective of the study was to determine whether the combination of 177Lu-PSMA-617 + SoC improved radiographic progression free survival (rPFS) over that obtained by administration of SoC alone in mHSPC patients.

The randomization was stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no).

Planned study duration: approximately 50 months. screening period: after signing ICF, patients were assessed for eligibility and were scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant was randomized via the interactive response technology (IRT) system.

Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at Radiographic progressive disease (rPD) following Blind Independent Review Committee (BIRC) confirmed rPD in both arms.

Prior treatment:

  • Up to 45 days of Luteinizing hormone releasing hormone (LHRH) agonist/antagonists was allowed prior to informed consent form (ICF) signature. If patient did not start the ADT prior randomization, ADT started as soon as possible and ideally no later than 2 weeks after randomization.
  • Up to 45 days of ARDT was allowed prior ICF signature. If patient did not start the ARDT prior randomization, ARDT started as soon as possible and ideally no later than 2 weeks after randomization. Patients received ARDT as per label instructions.

Randomization period:

The participant was randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.

Treatment period:

Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients received SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients began 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product was received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles.

Patients randomized to the control arm began receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol.

The primary endpoint of rPFS was assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician.

Participants from both arms also underwent PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD.

An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment.

Cross-over period:

After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =\< 7 days and enter the Post-treatment Follow-up.

Post-Treatment Follow-Up (Safety, Efficacy):

After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months.

Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first.

Survival Follow-Up:

After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Lutetium-177 PSMA-617
  • 177Lu-PSMA-617
  • Androgen receptor-directed therapy
  • ARDT
  • Androgen Deprivation Therapy
  • ADT
  • Metastatic Hormone sensitive prostate cancer
  • mHSPC
  • Radiographic progression free survival
  • rPFS
  • Prostate-specific membrane antigen
  • PSMA
  • Gallium-68 PSMA-11
  • 68Ga-PSMA-11
  • Radioligand Therapy
  • RLT
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Signed must be obtained prior to participation in the study
  2. Patients must be adults ≥18 years of age
  3. Patients must have an performance status of 0 to 2
  4. Patients must have a >9 months as determined by the study investigator
  5. Patients must have prostate cancer with or cytologically confirmed adenocarcinoma (current or prior of the prostate and/or metastatic site)
  6. Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan, and eligible as determined by the sponsor's central reader
  7. Patients must have at least one documented metastatic bone and/or soft tissue/visceral lesion documented in the following manners within 28 days prior randomization:

    1. Metastatic disease to the bone (in any distribution) visible on 99Tc-MDP bone scintigraphy on either pre-ADT scans or baseline scans AND/OR
    2. Lymph node metastases of any size or distribution. If lymph nodes are the only site of metastasis, then at least one must be at least 1.5 cm in short axis AND outside of the pelvis AND/OR
    3. Visceral metastases of any size or distribution. If a participant has a history of visceral metastases at any time prior to randomization, he should be coded as having visceral metastases at baseline (i.e., patients with visceral metastases prior to ADT that disappear at baseline will be counted as having visceral metastases and would therefore have high volume disease for stratification purposes).
  8. Patients must have adequate organ function:

    • Bone marrow reserve ≥1.5 x 109/L ≥100 x 109/L ≥9 g/dL
    • Hepatic Total ≤2 x the institutional (ULN). For patients with known Gilbert's Syndrome ≤3 x ULN is permitted (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN OR ≤5.0 x ULN for patients with liver metastases
    • Renal ≥ 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation
  9. Albumin ≥2.5 g/dL
  10. (HIV)-infected patients who are healthy and have a low risk of acquired immune deficiency syndrome (AIDS)-related outcomes can participate in this trial
  11. Patients must be:

Treatment naïve OR minimally treated with:

  • Up to 45 days of luteinizing hormone-releasing hormone (LHRH) agonist /antagonists or bilateral orchiectomy with or without first generation anti-androgen (e.g. bicalutamide, flutamide) for metastatic prostate cancer is allowed prior to ICF signature. If given, first generation anti-androgen must be discontinued prior to start of study therapy or after 45 days whatever happens first.
  • If received, prior LHRH agonist/antagonist with or without first generation anti-androgen use in the /neo-adjuvant setting must have been discontinued > 12 months prior to ICF signature AND must not have exceeded 24 months of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy.
  • Up to 45 days of CYP17 inhibitor or ARDT exposure for metastatic prostate cancer is allowed prior to ICF signature. No CYP17 inhibitor or ARDT exposure for earlier stages of prostate cancer is allowed.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study.

  1. Participants with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy
  2. Any prior systemic anti-prostate cancer therapy (with the exception of the drugs listed on inclusion criteria 11), including chemotherapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, immunotherapy or biological therapy (including monoclonal antibodies).
  3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or therapy
  4. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed
  5. Ongoing participation in any other clinical trial
  6. Use of other investigational drugs within 30 days prior to day of randomization
  7. Known to any of the study treatments or its or to drugs of similar chemical classes
  8. Transfusion for the sole purpose of making a participant eligible for study inclusion
  9. Participants with that are neurologically unstable, symptomatic, or receiving for the purpose of maintaining neurologic integrity. Participants with epidural disease, canal disease and prior cord involvement are allowed if those areas have been treated, are stable, and not neurologically impaired. Participants with parenchymal CNS metastasis (or a history of CNS metastasis), that have received prior therapy and are neurologically stable, asymptomatic and not receiving steroids for CNS metastases, are allowed, baseline and subsequent radiological imaging must include evaluation of the brain (magnetic resonance imaging (MRI) preferred or CT with contrast).
  10. Diagnosed with other that are expected to alter or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.
  11. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. Participants with an active documented COVID-19 infection (any grade of disease severity) at time of may be included only when completely recovered (in accordance with local guidance).
  12. Active cardiac disease defined as any of the following:

    • class 3/4 congestive heart failure within 6 months prior to ICF signature unless treated with improvement and echocardiogram or demonstrates EF > 45% with improvement in symptoms to class \< 3.
    • History or current diagnosis of abnormalities indicating significant risk of safety for participants in the study such as: Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • History of familial long syndrome or known family history of Torsades de Pointes
    • Cardiac or cardiac repolarization abnormality, including any of the following: History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature
  13. History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
  14. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
  15. Inability to complete the study imaging procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)
  16. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.
  17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,144 participants (actual)

Study arms

  • Experimental
    177Lu-PSMA-617 + SoC

    Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); Androgen receptor-directed therapy (ARDT) + Androgen deprivation therapy (ADT) is considered as SOC and treatment will be administered per the physician's order

    Drug: 177Lu-PSMA-617 · Drug: 68Ga-PSMA-11 · Drug: ARDT · Drug: ADT

  • Active comparator
    Standard of Care (SOC)

    For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order

    Drug: 68Ga-PSMA-11 · Drug: ARDT · Drug: ADT

Interventions

06

What researchers measure

Primary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan.

    Time frame: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months

Secondary outcomes

  1. Overall Survival (OS) (Key Secondary Endpoint)

    OS is defined as time to death for any cause

    Time frame: From date of randomization until date of death from any cause, assessed up to approx. 43 months

  2. Prostate-specific Antigen 90 (PSA90) Response

    PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months.

    Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]

  3. Time to Development of mCRPC

    Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.

    Time frame: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)

  4. Progression Free Survival (PFS)

    PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

  5. Second Progression Free Survival (PFS2)

    PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.

    Time frame: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

  6. Change in Nadir Level of PSA Lower Than 0.2 ng/ml

    Percentage of participants with PSA \< 0.2 ng/mL at months 12, 24 and 48 months/

    Time frame: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)

  7. Time to Radiographic Soft Tissue Progression (TTSTP)

    TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR).

    Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

  8. Time to First Symptomatic Skeletal Event (SSE)

    Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.

    Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)

  9. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

    Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

  10. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

    Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

  11. Duration of Response (DOR)

    DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause.

    Time frame: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

  12. Time to Response (TTR)

    TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).

    Time frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

  13. Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire

    FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

    Time frame: From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

  14. Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)

    EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual.

    Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

  15. Brief Pain Inventory-short Form (PBI-SF)

    The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

    Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

07

Results

Posted Nov 4, 2026
Limitations and caveats
The full analysis set that comprised all participants to whom study treatment was assigned by randomization was used for the All-Cause Mortality reporting. The safety set including all participants who received at least one dose of study treatment was used for SAEs and Other (not including serious) reporting.

Participant flow

1144 participants were enrolled from 19 countries, although 20 countries participated in the study.

Participant flow — Overall Study
Milestone177Lu-PSMA-617 + SoCStandard of Care (SOC)
Started572572
Treated567562
Not treated510
Discontinued from treatment187229
Ongoing treatment380333
Crossover participants (from soc to 177lu-psma-617)091
Completed380333
Not completed192239
Withdrew: Physician decision4942
Withdrew: Withdrawal by subject2831
Withdrew: Adverse event2720
Withdrew: Death1615
Withdrew: Protocol violation23
Withdrew: Lost to follow-up10
Withdrew: Progressive disease64118
Withdrew: Not treated510

Outcome measures

PrimaryRadiographic Progression Free Survival (rPFS)

rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan.

Time frame:
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
Reported as:
Median · months
Radiographic Progression Free Survival (rPFS)
months177Lu-PSMA-617 + SoCStandard of Care (SOC)
Radiographic Progression Free Survival (rPFS)NA (NA to NA)NA (29.73 to NA)
Statistical analysis
  • 177Lu-PSMA-617 + SoC vs Standard of Care (SOC) · Log Rank · p = = 0.002 · Hazard ratio (hr): 0.72 · 95% CI 0.58 to 0.90
SecondaryOverall Survival (OS) (Key Secondary Endpoint)

OS is defined as time to death for any cause

Time frame:
From date of randomization until date of death from any cause, assessed up to approx. 43 months
Reported as:
Median · months
Overall Survival (OS) (Key Secondary Endpoint)
months177Lu-PSMA-617 + SoCStandard of Care (SOC)
Overall Survival (OS) (Key Secondary Endpoint)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • 177Lu-PSMA-617 + SoC vs Standard of Care (SOC) · Log Rank · p = 0.125 · Hazard ratio (hr): 0.84 · 95% CI 0.63 to 1.13Stratified Log-rank test
SecondaryProstate-specific Antigen 90 (PSA90) Response

PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months.

Time frame:
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]

Results for this outcome have not been posted.

SecondaryTime to Development of mCRPC

Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.

Time frame:
From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryProgression Free Survival (PFS)

PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondarySecond Progression Free Survival (PFS2)

PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.

Time frame:
From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryChange in Nadir Level of PSA Lower Than 0.2 ng/ml

Percentage of participants with PSA \< 0.2 ng/mL at months 12, 24 and 48 months/

Time frame:
From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryTime to Radiographic Soft Tissue Progression (TTSTP)

TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR).

Time frame:
From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryTime to First Symptomatic Skeletal Event (SSE)

Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.

Time frame:
From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)

ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

Time frame:
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryDisease Control Rate (DCR)

DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

Time frame:
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR)

DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause.

Time frame:
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).

Time frame:
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryFunctional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

Time frame:
From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryQuality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)

EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual.

Time frame:
From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

SecondaryBrief Pain Inventory-short Form (PBI-SF)

The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 \[no pain\] to 10 \[pain as bad as you can imagine\]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

Time frame:
From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

Results for this outcome have not been posted.

Adverse events

Collected over On-treatment periods (assessed up to ~43 months): Lu+SoC, from 1st Lu dose to the later of 30 days after EOT/ARDT discontinuation or 41 days after last Lu dose SoC alone, from 1st post-randomization ARDT dose to the later of 30 days after last ARDT dose or EOT, ending before crossover Crossover Lu±SoC, from 1st crossover Lu dose to the later of 30 days after EOT or 41 days after last Lu dose Post-treatment periods: from end of treatment (or crossover treatment as applicable) to ~43 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
On-treatment Period 177Lu-PSMA-617 + SoC20/572 (3.5%)180/564 (31.9%)538/564 (95.4%)
On-treatment Period SoC Alone22/572 (3.8%)162/565 (28.7%)517/565 (91.5%)
On-treatment Period Crossover 177Lu-PSMA-617 +/- SoC9/91 (9.9%)27/91 (29.7%)74/91 (81.3%)
Post-treatment Period 177Lu-PSMA-617 + SoC65/572 (11.4%)14/564 (2.5%)20/564 (3.5%)
Post-treatment Period SoC Alone37/572 (6.5%)0/565 (0%)0/565 (0%)
Post-treatment Period Crossover 177Lu-PSMA-617 +/- SoC31/91 (34.1%)3/91 (3.3%)3/91 (3.3%)
Most frequent serious events
Showing 10 of 327
Most frequent serious events
EventOn-treatment Period 177Lu-PSMA-617 + SoCOn-treatment Period SoC AloneOn-treatment Period Crossover 177Lu-PSMA-617 +/- SoCPost-treatment Period 177Lu-PSMA-617 + SoCPost-treatment Period SoC AlonePost-treatment Period Crossover 177Lu-PSMA-617 +/- SoC
Back painMusculoskeletal and connective tissue disorders2/5647/5653/910/5640/5650/91
HaematuriaRenal and urinary disorders4/5647/5653/910/5640/5650/91
AnaemiaBlood and lymphatic system disorders6/5645/5652/910/5640/5651/91
Cardiac failureCardiac disorders0/5641/5652/910/5640/5650/91
VomitingGastrointestinal disorders3/5640/5652/910/5640/5650/91
General physical health deteriorationGeneral disorders6/5644/5651/911/5640/5652/91
Urinary tract infectionInfections and infestations4/5647/5652/911/5640/5650/91
Acute kidney injuryRenal and urinary disorders7/5645/5651/911/5640/5650/91
Pathological fractureMusculoskeletal and connective tissue disorders5/5647/5651/911/5640/5650/91
ThrombocytopeniaBlood and lymphatic system disorders1/5640/5651/911/5640/5650/91
Most frequent other events
Showing 10 of 50
Most frequent other events
EventOn-treatment Period 177Lu-PSMA-617 + SoCOn-treatment Period SoC AloneOn-treatment Period Crossover 177Lu-PSMA-617 +/- SoCPost-treatment Period 177Lu-PSMA-617 + SoCPost-treatment Period SoC AlonePost-treatment Period Crossover 177Lu-PSMA-617 +/- SoC
Dry mouthGastrointestinal disorders258/56421/56535/911/5640/5651/91
Hot flushVascular disorders164/564204/5653/911/5640/5650/91
FatigueGeneral disorders196/564157/56516/910/5640/5650/91
NauseaGastrointestinal disorders193/56453/56524/910/5640/5650/91
AnaemiaBlood and lymphatic system disorders149/56475/56518/916/5640/5650/91
ArthralgiaMusculoskeletal and connective tissue disorders111/564129/5659/911/5640/5650/91
Back painMusculoskeletal and connective tissue disorders100/564108/5657/913/5640/5650/91
ConstipationGastrointestinal disorders101/56490/56511/911/5640/5650/91
HypertensionVascular disorders74/56495/5654/910/5640/5651/91
AstheniaGeneral disorders92/56473/56512/911/5640/5650/91

Baseline characteristics

The FAS comprised all patients to whom study treatment was assigned by randomization.

Age, Continuous
Age, Continuous(years)177Lu-PSMA-617 + SoCStandard of Care (SOC)Total
Mean67.7 ± 8.5467.6 ± 8.3467.6 ± 8.44
Age, Customized
Age, Customized(Participants)177Lu-PSMA-617 + SoCStandard of Care (SOC)Total
Adults (18-64 years)185191376
From 65-84 years376372748
85 years and over11920
Sex/Gender, Customized
Sex/Gender, Customized(Participants)177Lu-PSMA-617 + SoCStandard of Care (SOC)Total
Male5725721144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)177Lu-PSMA-617 + SoCStandard of Care (SOC)Total
American Indian or Alaska Native123
Asian101118219
Black or African American262955
Native Hawaiian or Other Pacific Islander011
White356345701
Unknown8877165
08

Study locations

164 sites

Showing the first 100 of 164 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, Barthelemy P, Dai D, Lee JL, Nordquist L, Szmulewitz RZ, Wiechno P, Yovine A, Smith L, Bouillaud E, Sakharova O, Morris MJ; PSMAddition Investigators. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 6:S0140-6736(26)01092-5. doi: 10.1016/S0140-6736(26)01092-5. Online ahead of print. PubMed 42561994 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to participant-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jan 2025, 43 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion. A results delay was requested in Jan 2026.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 43 months is above that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

Completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Aug 2028, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Jan 22, 2021
StartActual
Jun 9, 2021
Primary completionActual
Jan 13, 2025
CompletionEst.
Aug 1, 2028was Feb 2027
Results delay requested
Jan 9, 2026
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Sites
2 sites added, 5 sites removed
Show 2 added (1 Netherlands, 1 Spain)
  • Novartis Investigative Site · Nijmegen, Netherlands
  • Novartis Investigative Site · Madrid, Spain
Show 5 removed
  • Mayo Clinic - Arizona Mayo Clinic Hospital · Scottsdale, United States
  • Mayo Clinic · Rochester, United States
  • Duke Raleigh Hospital · Raleigh, United States
  • Novartis Investigative Site · Nijmegen, Netherlands
  • Novartis Investigative Site · Majadahonda, Spain
Nov 4, 2026
Study completion
Feb 11, 2027→Aug 1, 2028
Nov 4, 2026
Enrollment
1140→1144
Nov 4, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • ChangedBefore Any condition that precludes raised arms positionNow Inability to complete the study imaging procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)
Nov 4, 2026
Interventions
Arm changed 177Lu-PSMA-617→177Lu-PSMA-617 + SoC; Standard of Care→Standard of Care (SOC)
Nov 4, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameRadiographic Progression Free Survival (rPFS)From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis) → From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
  • DescriptionRadiographic Progression Free Survival (rPFS): how it is measured was reworded
Nov 4, 2026
Documents
Publications
Results publication added: Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, B… PubMed 42561994 ↗
Nov 4, 2026
Secondary outcomes
7 edited, 1 time frame changed, 1 removed, 3 description edited
What changed in the outcomes
  • EditedProstate-specific antigenAntigen 90 (PSA90) responseResponseTime frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis) → From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
  • EditedtimeTime to developmentDevelopment of mCRPCTime frame: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
  • EditedsecondSecond Progression Free Survival (PFS2)Time frame: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
  • EditedChange in nadir levelNadir Level of PSA lower thanLower Than 0.2 ng/mlTime frame: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
  • EditedTime to radiographic soft tissue progressionRadiographic Soft Tissue Progression (TTSTP)Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
  • EditedTime to first symptomatic skeletal eventFirst Symptomatic Skeletal Event (SSE).Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
  • EditedEuropean Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
  • RemovedNumber of participants with Treatment Emergent Adverse EventsTime frame: From randomization till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)
  • Time frameOverall Survival (OS) (Key Secondary Endpoint)From date of randomization until date of death from any cause, assessed up to 50 months (estimated final OS analysis) → From date of randomization until date of death from any cause, assessed up to approx. 43 months
  • DescriptionDisease Control Rate (DCR): how it is measured was reworded
  • DescriptionDuration of Response (DOR): how it is measured was reworded
  • DescriptionOverall Response Rate (ORR): how it is measured was reworded
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Publications Results publication added: Tagawa ST, Sartor O, Piulats JM, Saad F, Fizazi K, Reid A, Beltran H, Kramer G, Mahammedi H, Eiber M, Gupta S, Castellano D, Hauke R, Kim H, Kwak C, Pang ST, B… PubMed 42561994 ↗
    2 sites added, 5 sites removed
    Show 2 added (1 Netherlands, 1 Spain)
    • Novartis Investigative Site · Nijmegen, Netherlands
    • Novartis Investigative Site · Madrid, Spain
    Show 5 removed
    • Mayo Clinic - Arizona Mayo Clinic Hospital · Scottsdale, United States
    • Mayo Clinic · Rochester, United States
    • Duke Raleigh Hospital · Raleigh, United States
    • Novartis Investigative Site · Nijmegen, Netherlands
    • Novartis Investigative Site · Majadahonda, Spain
    Study completion Feb 11, 2027→Aug 1, 2028
    Enrollment 1140→1144
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • ChangedBefore Any condition that precludes raised arms positionNow Inability to complete the study imaging procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameRadiographic Progression Free Survival (rPFS)From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis) → From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
    • DescriptionRadiographic Progression Free Survival (rPFS): how it is measured was reworded
    Secondary outcomes 7 edited, 1 time frame changed, 1 removed, 3 description edited
    What changed in the outcomes
    • EditedProstate-specific antigenAntigen 90 (PSA90) responseResponseTime frame: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis) → From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
    • EditedtimeTime to developmentDevelopment of mCRPCTime frame: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
    • EditedsecondSecond Progression Free Survival (PFS2)Time frame: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
    • EditedChange in nadir levelNadir Level of PSA lower thanLower Than 0.2 ng/mlTime frame: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
    • EditedTime to radiographic soft tissue progressionRadiographic Soft Tissue Progression (TTSTP)Time frame: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
    • EditedTime to first symptomatic skeletal eventFirst Symptomatic Skeletal Event (SSE).Time frame: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
    • EditedEuropean Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)Time frame: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
    • RemovedNumber of participants with Treatment Emergent Adverse EventsTime frame: From randomization till 30 days safety follow-up, assessed up to 50 months (estimated final OS analysis)
    • Time frameOverall Survival (OS) (Key Secondary Endpoint)From date of randomization until date of death from any cause, assessed up to 50 months (estimated final OS analysis) → From date of randomization until date of death from any cause, assessed up to approx. 43 months
    • DescriptionDisease Control Rate (DCR): how it is measured was reworded
    • DescriptionDuration of Response (DOR): how it is measured was reworded
    • DescriptionOverall Response Rate (ORR): how it is measured was reworded
    Interventions Arm changed 177Lu-PSMA-617→177Lu-PSMA-617 + SoC; Standard of Care→Standard of Care (SOC)
    + 6 other changes: identifiers, verification date, registry dates, description, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04720157
Collaborators
Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Jun 9, 2021
Primary completion
Jan 13, 2025
Completion
Aug 1, 2028 (estimated)
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Start the discussion